Factors Affecting Liver Fibrosis in Human Immunodeficiency Virus-And Hepatitis C Virus-Coinfected Patients: Impact of Protease Inhibitor Therapy

• DOI: 10.1053/jhep.2001.26517
• Publication Date: 2002-08-25T03:46:10Z
• Authors: Yves Benhamou; Vincent Di Martino; Marie Bochet; Geneviève Colombet; Vincent Thibault; Amélie Liou; Christine Katlama; Thierry Poynard
• Keywords: Protease inhibitor (pharmacology); Hepatitis C

Hepatitis C virus (HCV)–related liver fibrosis progression is accelerated in human immunodeficiency (HIV)–infected patients. The effect of protease inhibitor (PI) therapy on unknown. aim this work was to analyze the impact PI HCV–related HIV/HCV coinfected We evaluated a long–term follow–up retrospective cohort study influence antiretroviral containing 182 consecutive At biopsy, 63 patients had received and 119 never been treated with PI. Relationships between histologic features, age, alcohol consumption, CD4 cell count, HIV–RNA load, regimens were analyzed. Liver stage lower receiving PIs by comparison who ( P = .03). 5–, 15–, 25–year cirrhosis rates 2% versus 5%, 5% 18%, 9% 27%, respectively, compared PI–untreated .0006). Multivariate analysis identified 4 independent predictors cirrhosis: absence (relative risk [RR] 4.74, 95% confidence interval [CI], 1.34–16.67), heavy consumption (≥ 50 g daily) (RR 4.71, CI, 1.92–11.57), low count (<200/μL) 2.74, 1.17–6.41), age at HCV contamination (≥20 years) 2.37, 1.04–5.38). In conclusion, might not accelerate cirrhosis. Furthermore, chronic use together reduction maintenance high could have beneficial